Krystal Biotech, Inc. develops and commercializes genetic medicines, focusing on severe, life-threatening, or rare diseases with limited treatment options. Its first product, VYJUVEK®, is a redosable gene therapy for dystrophic epidermolysis bullosa. The company utilizes a modified HSV-1 vector platform to create its therapies and operates two GMP manufacturing facilities. Krystal's pipeline includes various genetic therapies aimed at addressing the root causes of serious genetic disorders.
